<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Adaptation to <z:mp ids='MP_0005039'>hypoxia</z:mp> is a driving force for <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> that leads to therapy resistance and poor clinical outcome </plain></SENT>
<SENT sid="1" pm="."><plain>Hypoxic responses are mainly mediated by <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible transcription factor-1 (HIF-1) </plain></SENT>
<SENT sid="2" pm="."><plain>One critical HIF-1 target mediating <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> is <z:chebi fb="0" ids="32568">lysyl</z:chebi> oxidase (LOX), which catalyzes cross-linking of collagens and elastin in the extracellular matrix, thereby regulating tissue tensile strength </plain></SENT>
<SENT sid="3" pm="."><plain>Paradoxically, LOX has been reported to be both upregulated and downregulated in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, especially in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, we hypothesized that LOX might regulate expression of HIF-1 to create a self-timing regulatory circuit </plain></SENT>
<SENT sid="5" pm="."><plain>Using human colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cell lines in which HIF-1 and LOX expression could be modulated, we showed that LOX induction enhanced HIF-1 expression, whereas LOX silencing reduced it </plain></SENT>
<SENT sid="6" pm="."><plain>Mechanistic investigations revealed that LOX activated the PI3K (<z:chebi fb="0" ids="16749">phosphoinositide</z:chebi> 3-kinase)-Akt signaling pathway, thereby upregulating HIF-1α protein synthesis in a manner requiring LOX-mediated <z:chebi fb="17" ids="16240">hydrogen peroxide</z:chebi> production </plain></SENT>
<SENT sid="7" pm="."><plain>Consistent with these results, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell proliferation was stimulated by secreted and active LOX in an HIF-1α-dependent fashion </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, <z:mp ids='MP_0003815'>nude</z:mp> mice xenograft assays established that HIF-1 potentiated LOX action on <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in vivo </plain></SENT>
<SENT sid="9" pm="."><plain>Taken together, these findings provide compelling evidence that LOX and HIF-1 act in synergy to foster <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation, and they suggest that HIF-1/LOX mutual regulation is a pivotal mechanism in the adaptation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells to <z:mp ids='MP_0005039'>hypoxia</z:mp> </plain></SENT>
</text></document>